Debt-to-equity in % of Nabriva Therapeutics plc from Q3 2017 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nabriva Therapeutics plc quarterly Debt-to-equity history and change rate from Q3 2017 to Q2 2023.
  • Nabriva Therapeutics plc Debt-to-equity for the quarter ending 30 Jun 2023 was 1.3K %, a 2575% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Nabriva Therapeutics plc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2023 1.3K +1.25K +2575% 30 Jun 2023
Q1 2023 169 +125 +287% 31 Mar 2023
Q4 2022 85.6 +42.4 +98.1% 31 Dec 2022
Q3 2022 57.9 +11.8 +25.6% 30 Sep 2022
Q2 2022 48.4 -1.42 -2.85% 30 Jun 2022
Q1 2022 43.7 -10.1 -18.8% 31 Mar 2022
Q4 2021 43.2 -22.3 -34% 31 Dec 2021
Q3 2021 46.1 -35 -43.1% 30 Sep 2021
Q2 2021 49.8 -50.6 -50.4% 30 Jun 2021
Q1 2021 53.8 -61 -53.1% 31 Mar 2021
Q4 2020 65.4 -36.7 -35.9% 31 Dec 2020
Q3 2020 81.1 -2.56 -3.06% 30 Sep 2020
Q2 2020 100 +47.5 +90% 30 Jun 2020
Q1 2020 115 +76.8 +202% 31 Mar 2020
Q4 2019 102 +77.1 +309% 31 Dec 2019
Q3 2019 83.7 +67.9 +431% 30 Sep 2019
Q2 2019 52.9 +37.2 +237% 30 Jun 2019
Q1 2019 38 +19.5 +106% 31 Mar 2019
Q4 2018 25 +3.52 +16.4% 31 Dec 2018
Q3 2018 15.8 -6.82 -30.2% 30 Sep 2018
Q2 2018 15.7 30 Jun 2018
Q1 2018 18.4 31 Mar 2018
Q4 2017 21.5 31 Dec 2017
Q3 2017 22.6 30 Sep 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.